论文部分内容阅读
[摘要] 目的 探讨孟鲁司特钠联合布地奈德治疗支气管哮喘的临床疗效。 方法 将200例支气管哮喘患者随机分成两组，每组各100例。两组均予抗生素抗感染、多索茶碱平喘，布地奈德 1～2 mg加入生理盐水 3 mL中雾化吸入，每天2次，症状缓解后可改为吸入 0.5～1.0 mg/次，2次/d。观察组同时加用孟鲁司特咀嚼片口服10 mg/次，睡前服用，每天1次。疗程3个月。比较两组的临床疗效、肺功能及哮喘发作次数。 结果 观察组患者治疗后的总有效率为98.0%，明显高于对照组患者治疗后的70.0%（P<0.05）。观察组患者治疗后的哮喘发作次数为（1.17±0.20）次/d，显著低于治疗前及对照组（P<0.05）。观察组患者治疗后FEV1/FVC为（80.29±13.43）， PEF为（87.25±11.32）%，均显著高于治疗前及对照组（P<0.05）。 结论 孟鲁司特钠联合布地奈德治疗支气管哮喘可以提高疗效，减少哮喘发作次数，改善肺功能，值得推广和应用。
[关键词] 支气管哮喘；孟鲁司特钠；布地奈德；肺功能
[中图分类号] R562.25 [文献标识码] B [文章编号] 1673-9701（2017）14-0079-03
[Abstract] Objective To investigate the clinical efficacy of montelukast combined with budesonide in the treatment of bronchial asthma. Methods A total of 200 cases of bronchial asthma patients were randomly divided into two groups， each group of 100 cases. Two groups were treated with antibiotics， doxofylline antiasthmatic； budesonide 1-2 mg in saline inhalation of 3 mL， 2 times a day， symptoms were changed after the inhalation of 0.5-1.0 mg/time， 2 times/d inhalation. The observation group was treated with montelukast chewable tablets orally 10 mg/times， before going to bed， every day for 1 time. Course of treatment for 3 months. The clinical efficacy， lung function and the number of asthma attacks were compared between the two groups. Results The total effective rate of the observation group was 98.0%， which was significantly higher than 70.0% of the control group after treatment（P<0.05）. The number of asthma attacks in the observation group was（1.17±0.20） times/d， significantly lower than that before treatment and control group（P<0.05）. The FEV1/FVC of the patients in the observation group was（80.29±13.43）， the PEF was（87.25±11.32）%， significantly higher than that before treatment and control group（P<0.05）. Conclusion Montelukast sodium combined with budesonide in the treatment of bronchial asthma can improve the efficacy， reduce the number of asthma attacks， improve lung function， it is worthy of promotion and application.
[Key words] Bronchial asthma； Montelukast sodium； Budesonide； Lung function
支氣管哮喘為呼吸系统的常见病、多发病，常伴发气道阻塞。缓解临床症状、改善患者的肺功能及防止病情恶化是目前临床治疗支气管哮喘的主要目的[1]。孟鲁司特钠是常用的白三烯受体拮抗剂之一，布地奈德为常用的糖皮质激素之一，研究发现二者联用对于缓解气道受阻、改善患者肺功能具有较好的治疗效果[2-3]。本研究旨在探讨孟鲁司特钠联合布地奈德治疗支气管哮喘的临床疗效，现报道如下。
1 对象与方法
1.1研究对象
将2014年7月～2016年6月在我院治疗的200例支气管哮喘患者纳入本研究，患者治疗前均未应用糖皮质激素及白三烯受体拮抗剂，排除合并严重肝肾功能不全及精神疾病、妊娠期及哺乳期妇女。其中男110例，女90例，年龄22～72岁，平均（46.3±5.1）岁。随机分成两组，每组各100例。两组患者的性别、年龄等一般资料比较，差异无统计学意义（P>0.05），具有可比性。
[关键词] 支气管哮喘；孟鲁司特钠；布地奈德；肺功能
[中图分类号] R562.25 [文献标识码] B [文章编号] 1673-9701（2017）14-0079-03
[Abstract] Objective To investigate the clinical efficacy of montelukast combined with budesonide in the treatment of bronchial asthma. Methods A total of 200 cases of bronchial asthma patients were randomly divided into two groups， each group of 100 cases. Two groups were treated with antibiotics， doxofylline antiasthmatic； budesonide 1-2 mg in saline inhalation of 3 mL， 2 times a day， symptoms were changed after the inhalation of 0.5-1.0 mg/time， 2 times/d inhalation. The observation group was treated with montelukast chewable tablets orally 10 mg/times， before going to bed， every day for 1 time. Course of treatment for 3 months. The clinical efficacy， lung function and the number of asthma attacks were compared between the two groups. Results The total effective rate of the observation group was 98.0%， which was significantly higher than 70.0% of the control group after treatment（P<0.05）. The number of asthma attacks in the observation group was（1.17±0.20） times/d， significantly lower than that before treatment and control group（P<0.05）. The FEV1/FVC of the patients in the observation group was（80.29±13.43）， the PEF was（87.25±11.32）%， significantly higher than that before treatment and control group（P<0.05）. Conclusion Montelukast sodium combined with budesonide in the treatment of bronchial asthma can improve the efficacy， reduce the number of asthma attacks， improve lung function， it is worthy of promotion and application.
[Key words] Bronchial asthma； Montelukast sodium； Budesonide； Lung function
支氣管哮喘為呼吸系统的常见病、多发病，常伴发气道阻塞。缓解临床症状、改善患者的肺功能及防止病情恶化是目前临床治疗支气管哮喘的主要目的[1]。孟鲁司特钠是常用的白三烯受体拮抗剂之一，布地奈德为常用的糖皮质激素之一，研究发现二者联用对于缓解气道受阻、改善患者肺功能具有较好的治疗效果[2-3]。本研究旨在探讨孟鲁司特钠联合布地奈德治疗支气管哮喘的临床疗效，现报道如下。
1 对象与方法
1.1研究对象
将2014年7月～2016年6月在我院治疗的200例支气管哮喘患者纳入本研究，患者治疗前均未应用糖皮质激素及白三烯受体拮抗剂，排除合并严重肝肾功能不全及精神疾病、妊娠期及哺乳期妇女。其中男110例，女90例，年龄22～72岁，平均（46.3±5.1）岁。随机分成两组，每组各100例。两组患者的性别、年龄等一般资料比较，差异无统计学意义（P>0.05），具有可比性。